Phase 1 Kidney Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a type of kidney cancer called clear cell renal cell carcinoma (ccRCC) that has spread or cannot be surgically removed, and for which standard treatments no longer exist or are no longer working.
• People whose tumor tissue test shows that at least 10% of cancer cells carry a protein called CD70 (confirmed by a lab test on a sample of the original kidney tumor or a site where the cancer has spread).
• People who have at least one tumor that is large enough to be measured on a scan or X-ray (at least 2 cm on chest X-ray, or at least 1 cm on CT or MRI scan).
• People who have previously received at least one treatment from each of two specific drug types — an immune checkpoint inhibitor (ICI) and a tyrosine kinase inhibitor (TKI) — and whose cancer clearly got worse while on the immune checkpoint inhibitor treatment.
• People aged 18 years or older.
• People who weigh at least 40 kg (approximately 88 pounds).
• People who are in good enough general health to carry out normal daily activities with no more than minor limitations (confirmed by a standard performance scale used by doctors).
• People whose kidneys, liver, heart, lungs, and blood counts are functioning at levels that meet the specific laboratory values required by the trial (the trial site can provide exact details).
• People who have had localised radiation treatment to one or more cancer sites before the trial's preparatory chemotherapy, as long as there are other measurable cancer sites that were not irradiated.
• People who have been off their last chemotherapy, targeted therapy, or similar cancer treatment for at least 2 weeks before the trial's preparatory chemotherapy begins.
• People who have been off any previous cell-based cancer therapy for at least 3 months before joining.
• People who are able to read and sign a written consent form agreeing to take part.
• People who are able to agree to long-term follow-up as required by the trial.
• People of childbearing potential who agree to use effective contraception during the trial and for up to 3 months after completing treatment, and who have a negative pregnancy test at the time of screening.
• People who are not pregnant or breastfeeding.

Who may not be able to join:

• People who are still experiencing significant side effects (Grade 2 or higher) from a previous cancer treatment that have not yet settled down to a mild level (Grade 1 or lower).
• People who have an active infection requiring treatment through a drip (IV antibiotics or antifungals), or an infection that is not responding to treatment (minor infections such as a urinary tract infection or throat infection that are responding to treatment may still be acceptable — confirm with trial site).
• People with a known active hepatitis B or hepatitis C infection.
• People known to have HIV.
• People with an active neurological (brain or nerve) disorder.
• People who have had an active autoimmune disease (where the immune system attacks the body) within the past 12 months, with the exception of mild psoriasis or well-controlled thyroid conditions.
• People with a condition called amyloidosis or POEMS syndrome.
• People with cancer that has spread to the brain or spinal cord in a way that is causing symptoms or is not under control (if radiation to this area is needed, a waiting period of at least 14 days after radiation is required before joining).
• People who have had another cancer diagnosis within the past 2 years, with some exceptions for certain very early-stage or skin-only cancers that were fully treated, or for certain low-risk cancers that a doctor determines would not interfere with participation (confirm with trial site).
• People with serious heart conditions, including severe heart failure, a heart attack or stroke within the past 26 weeks, unstable chest pain within the past 13 weeks (unless a procedure such as a stent has corrected it), severe aortic valve narrowing, an uncontrolled abnormal heart rhythm, a hereditary heart rhythm condition called long QT syndrome, or a specific abnormal heart reading on an ECG (confirm with trial site).
• People who have had major surgery within 4 weeks before starting the trial's preparatory chemotherapy.
• People currently taking part in another clinical trial involving an experimental treatment.
• People currently taking other cancer-fighting treatments.
• People currently taking steroid tablets or injections at doses above a low daily threshold, with exceptions for steroids applied to the skin, eyes, nose, or lungs (confirm with trial site for the specific dose limit).
• People who have received certain immune-suppressing drugs (antithymocyte globulin within 14 days, or alemtuzumab within 28 days) before starting the trial.
• People who are currently taking other medicines that suppress the immune system.
• People who have received a live vaccine (such as measles, chickenpox, yellow fever, or nasal flu spray) within 6 weeks before the cell treatment infusion (standard injected flu and COVID-19 vaccines are generally permitted — confirm with trial site).
• Children under 18 years of age, as no safety data are yet available for this age group.

Important: Always verify eligibility with the trial site directly before applying.